Malcolm Rowland: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
DGG (talk | contribs)
316,874 edits
Cleaning up accepted Articles for creation submission (AFCH 0.9.1)
No edit summary
Line 19: Line 19:


== Academic career ==
== Academic career ==
Following his Ph.D. degree research into the pharmacokinetics of amphetamines<ref>https://catalogue.libraries.london.ac.uk/search~S16?/aRowland%2C+M./arowland+m/-3%2C-1%2C0%2CB/frameset&FF=arowland+m&1%2C1%2C</ref>, he took up a postdoctoral research appointment in the laboratory of Sidney Riegelman, School of Pharmacy, University of California, San Francisco (1965-1967), studying the pharmacokinetics of aspirin, and then took up a faculty position there (1967-75). While at UCSF<ref>{{Cite web|url=https://pharm.ucsf.edu/history-bts/riegelman|title = 1967–1978: The Riegelman Chairship · History of the Department of Bioengineering and Therapeutic Sciences}}</ref> . Rowland became a member of the joint Pharmacy-Medicine NIGMS funded program in Clinical Pharmacology, and moved his research from a prevailing descriptive approach to a more mechanistic, physiologically-based one<ref>N Benowitz, F P Forsyth, K L Melmon, M Rowland (1974). Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model. Clin Pharmacol Ther. Jul;16(1):87-98. https://doi.org/10.1002/cpt1974161part187</ref>, including the clearance concept<ref>Malcolm Rowland, Leslie Z. Benet & Garry G. Graham (1973). Clearance concepts in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics. Apr;1(2):123-36. https://link.springer.com/article/10.1007/BF01059626</ref>,<ref>K Sandy Pang, Malcolm Rowland (1977). Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. Journal of Pharmacokinetics Biopharmaceutics. Dec;5(6):625-53. https://link.springer.com/article/10.1007/BF01059688</ref> , that helped lay the foundations of modern pharmacokinetics. Together with Riegelman and Leslie Benet he founded the ''Journal of Pharmacokinetics and Biopharmaceutics'' (1973)<ref>{{Cite journal|url=https://link.springer.com/article/10.1007/s10928-020-09674-4|doi=10.1007/s10928-020-09674-4|title=On the shoulders of giants…|year=2020|last1=Bonate|first1=Peter L.|journal=Journal of Pharmacokinetics and Pharmacodynamics|volume=47|issue=1|page=1|pmid=31960232|s2cid=210717345}}</ref> (renamed ''Journal of Pharmacokinetics and Pharmacodynamics'', 2001), and was a senior editor of it until 2007.
Following his Ph.D. degree research into the pharmacokinetics of amphetamines<ref>https://catalogue.libraries.london.ac.uk/search~S16?/aRowland%2C+M./arowland+m/-3%2C-1%2C0%2CB/frameset&FF=arowland+m&1%2C1%2C</ref>, he took up a postdoctoral research appointment in the laboratory of Sidney Riegelman, School of Pharmacy, University of California, San Francisco (1965-1967), studying the pharmacokinetics of aspirin, and then took up a faculty position there (1967-75). While at UCSF<ref>{{Cite web|url=https://pharm.ucsf.edu/history-bts/riegelman|title = 1967–1978: The Riegelman Chairship · History of the Department of Bioengineering and Therapeutic Sciences}}</ref> . Rowland became a member of the joint Pharmacy-Medicine NIGMS funded program in Clinical Pharmacology, and moved his research from a prevailing descriptive approach to a more mechanistic, physiologically-based one,<ref>{{cite journal |last1=Benowitz |first1=Neal |last2=Forsyth |first2=Ralph P. |last3=Melmon |first3=Kenneth L. |last4=Rowland |first4=Malcolm |title=Lidocaine disposition kinetics in monkey and man; I. Prediction by a perfusion model |journal=Clinical Pharmacology & Therapeutics |date=July 1974 |volume=16 |issue=1part1 |pages=87–98 |doi=10.1002/cpt1974161part187 }}</ref> including the clearance concept<ref>{{cite journal |last1=Rowland |first1=Malcolm |last2=Benet |first2=Leslie Z. |last3=Graham |first3=Garry G. |title=Clearance concepts in pharmacokinetics |journal=Journal of Pharmacokinetics and Biopharmaceutics |date=April 1973 |volume=1 |issue=2 |pages=123–136 |doi=10.1007/BF01059626 }}</ref><ref>{{cite journal |last1=Pang |first1=K. Sandy |last2=Rowland |first2=Malcolm |title=Hepatic clearance of drugs. I. Theoretical considerations of a 'well-stirred' model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance |journal=Journal of Pharmacokinetics and Biopharmaceutics |date=December 1977 |volume=5 |issue=6 |pages=625–653 |doi=10.1007/BF01059688 }}</ref> that helped lay the foundations of modern pharmacokinetics. Together with Riegelman and Leslie Benet he founded the ''Journal of Pharmacokinetics and Biopharmaceutics'' (1973)<ref>{{cite journal |last1=Bonate |first1=Peter L. |title=On the shoulders of giants… |journal=Journal of Pharmacokinetics and Pharmacodynamics |date=February 2020 |volume=47 |issue=1 |pages=1|doi=10.1007/s10928-020-09674-4 |pmid=31960232 |s2cid=210717345 }}</ref> (renamed ''Journal of Pharmacokinetics and Pharmacodynamics'', 2001), and was a senior editor of it until 2007.


In 1975 Rowland returned to the United Kingdom to take up a position of Professor of Pharmacy, University of Manchester where he extended his research on physiologically based pharmacokinetics<ref>Michael S. Roberts & Malcolm Rowland (1986). A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. Journal of Pharmacokinetics and Biopharmaceutics 14, 227–260. https://link.springer.com/article/10.1007%2FBF01106706</ref>,<ref>Cheung, S.Y.A., Rodgers, T., Aarons, L., Gueorguieva, I, Dickenson, G.L., Murby, S, Brown, C., Collins, B., Rowland, M (2018). Whole body physiologically based modelling of beta-blockers in the rat: Events in tissues and plasma following an intravenous bolus dose. Brit. J. Pharmacol. 175 67-83. PMID: 29053169, DOI: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.14071</ref>, including development of an in silico method for predicting tissue distribution of drugs based on tissue composition and physicochemical properties<ref>Rodgers, T. and Rowland, M (2006). Physiologically-Based Pharmacokinetic Modeling 2: Predicting the Tissue Distribution of Acids, Very Weak Bases, Neutrals and Zwitterions. J. Pharm. Sci. 95 1238-57. PMID: 16639716 DOI: https://jpharmsci.org/article/S0022-3549(16)32034-2/fulltext</ref>. In 1983 he founded Medeval<ref>{{Cite web|url=https://www.bmh.manchester.ac.uk/research/impact/drug-development/|title=Drug development &#124; the University of Manchester}}</ref>, undertaking early stage clinical evaluation of new medicines under development. Together with Brian Houston and Leon Aarons he established the Centre for Applied Pharmacokinetic Research (1996)<ref>https://www.capkr.manchester.ac.uk</ref>. He has promoted the application of microdosing in clinical drug development.<ref>Graham Lappin, Yoko Shishikura, Roeline Jochemsen, Richard John Weaver, Charlotte Gesson, Brian Houston, Berend Oosterhuisd, Ole J. Bjerrum, Grzegorz Grynkiewiczf, Jane Alder, Malcolm Rowland, Colin Garner (2011). Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur. J. Pharm. Sci 2011, 43 141–150; PMID: 21540108, DOI: https://www.sciencedirect.com/science/article/abs/pii/S0928098711001047?via%3Dihub</ref>,<ref>Tal Burt, Graeme Young, Wooin Lee, Hiroyuki Kusuhara, Oliver Langer, Malcolm Rowland, Yuichi Sugiyama (2020). Phase-0 including microdosing approaches: Time for mainstream application in drug development? Nature Reviews Drug Discovery Development. 19: 801-818. PMID: 32901140, DOI: https://www.nature.com/articles/s41573-020-0080-x</ref>
In 1975 Rowland returned to the United Kingdom to take up a position of Professor of Pharmacy, University of Manchester where he extended his research on physiologically based pharmacokinetics<ref>Michael S. Roberts & Malcolm Rowland (1986). A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. Journal of Pharmacokinetics and Biopharmaceutics 14, 227–260. https://link.springer.com/article/10.1007%2FBF01106706</ref>,<ref>Cheung, S.Y.A., Rodgers, T., Aarons, L., Gueorguieva, I, Dickenson, G.L., Murby, S, Brown, C., Collins, B., Rowland, M (2018). Whole body physiologically based modelling of beta-blockers in the rat: Events in tissues and plasma following an intravenous bolus dose. Brit. J. Pharmacol. 175 67-83. PMID: 29053169, DOI: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.14071</ref>, including development of an in silico method for predicting tissue distribution of drugs based on tissue composition and physicochemical properties<ref>Rodgers, T. and Rowland, M (2006). Physiologically-Based Pharmacokinetic Modeling 2: Predicting the Tissue Distribution of Acids, Very Weak Bases, Neutrals and Zwitterions. J. Pharm. Sci. 95 1238-57. PMID: 16639716 DOI: https://jpharmsci.org/article/S0022-3549(16)32034-2/fulltext</ref>. In 1983 he founded Medeval<ref>{{Cite web|url=https://www.bmh.manchester.ac.uk/research/impact/drug-development/|title=Drug development &#124; the University of Manchester}}</ref>, undertaking early stage clinical evaluation of new medicines under development. Together with Brian Houston and Leon Aarons he established the Centre for Applied Pharmacokinetic Research (1996)<ref>https://www.capkr.manchester.ac.uk</ref>. He has promoted the application of microdosing in clinical drug development.<ref>Graham Lappin, Yoko Shishikura, Roeline Jochemsen, Richard John Weaver, Charlotte Gesson, Brian Houston, Berend Oosterhuisd, Ole J. Bjerrum, Grzegorz Grynkiewiczf, Jane Alder, Malcolm Rowland, Colin Garner (2011). Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur. J. Pharm. Sci 2011, 43 141–150; PMID: 21540108, DOI: https://www.sciencedirect.com/science/article/abs/pii/S0928098711001047?via%3Dihub</ref>,<ref>Tal Burt, Graeme Young, Wooin Lee, Hiroyuki Kusuhara, Oliver Langer, Malcolm Rowland, Yuichi Sugiyama (2020). Phase-0 including microdosing approaches: Time for mainstream application in drug development? Nature Reviews Drug Discovery Development. 19: 801-818. PMID: 32901140, DOI: https://www.nature.com/articles/s41573-020-0080-x</ref>

Revision as of 12:36, 18 April 2022

Malcolm Rowland
Born
London, UK
NationalityEnglish
Known forPharmacy

Malcolm Rowland FBPhS[1] (born August 5, 1939, London) is Emeritus Professor of Pharmacy, University of Manchester[2], and Adjunct Professor, University of California San Francisco. His research in pharmacology, has been particularly in physiologically based pharmacokinetics (that deals with the movement in time of drugs and their metabolites within the body) [3]. He has written several textbooks on the subject.

He studied Pharmacy at Chelsea College (now Kings College), an internal college of the University of London, gaining a B.Pharm (1961) and subsequently a Ph.D (1965).

Academic career

Following his Ph.D. degree research into the pharmacokinetics of amphetamines[4], he took up a postdoctoral research appointment in the laboratory of Sidney Riegelman, School of Pharmacy, University of California, San Francisco (1965-1967), studying the pharmacokinetics of aspirin, and then took up a faculty position there (1967-75). While at UCSF[5] . Rowland became a member of the joint Pharmacy-Medicine NIGMS funded program in Clinical Pharmacology, and moved his research from a prevailing descriptive approach to a more mechanistic, physiologically-based one,[6] including the clearance concept[7][8] that helped lay the foundations of modern pharmacokinetics. Together with Riegelman and Leslie Benet he founded the Journal of Pharmacokinetics and Biopharmaceutics (1973)[9] (renamed Journal of Pharmacokinetics and Pharmacodynamics, 2001), and was a senior editor of it until 2007.

In 1975 Rowland returned to the United Kingdom to take up a position of Professor of Pharmacy, University of Manchester where he extended his research on physiologically based pharmacokinetics[10],[11], including development of an in silico method for predicting tissue distribution of drugs based on tissue composition and physicochemical properties[12]. In 1983 he founded Medeval[13], undertaking early stage clinical evaluation of new medicines under development. Together with Brian Houston and Leon Aarons he established the Centre for Applied Pharmacokinetic Research (1996)[14]. He has promoted the application of microdosing in clinical drug development.[15],[16]

He headed the School of Pharmacy at Manchester on two occasions, 1988-1991 and 1998-2001, periods involving the move to clinical pharmacy and moving Pharmacy from the Faculty of Science and Engineering to the Faculty of Medicine, in recognition of the changing professional role of pharmacists from fabricator to health care advisor on medicines. Rowland has trained 90 Ph.D. students and scientists from a variety of disciplines. He also established ongoing annual postgraduate workshops in basic pharmacokinetics with Tomas Tozer (1977), and in advanced methods in pharmacokinetics and pharmacodynamics with Lewis Sheiner (1981).[17]

Rowland was president of EUFEPS (European Federation for Pharmaceutical Sciences, 1996-1999)[18], and a Vice-President of FIP (International Pharmaceutical Federation,2001-2009).[19]

Published works

Rowland has published over 270 research articles in international peer-reviewed journals, and over 60 book chapters and conference reports. He co-authored with Thomas Tozer two standard textbooks: Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, now in its 5th edition, and Essentials of Pharmacokinetics and Pharmacodynamics.[20]

Honours and Awards

He received honorary degrees from University of Poitiers, France (D.Sc.1981), Uppsala University , Sweden (FarmDhc, 1989)[21], and Athens University, Greece ( D.Sc., 2011)[22]. He was made Fellow, Academy of Medical Sciences (2001), Fellow, British Pharmacological Society (2012), and Honorary Fellow, American College of Clinical Pharmacology (2003)[23]. He received the Scheele Award (Swedish Academy of Pharmaceutical Sciences, 1984)[24], the Distinguished Investigator Award (American College of Clinical Pharmacology, 2007), the New Safe Medicines Faster Award (EUFEPS, 2009), Research Achievement Award in Pharmacokinetics (American Association of Pharmaceutical Scientists, 1994)[25], the Sheiner-Beal Award in Pharmacometrics (American Society of Clinical Pharmacology and Therapeutics, 2012)[26] and the Ariens Award (Dutch Pharmacological Society, 2020)[27]., as well as the Harrison Memorial Medal (Royal Pharmaceutical Society of Great Britain, 1992)[28] and Host Madsen Medal (International Pharmaceutical Federation, 2011)[29]

Personal life

Malcolm married Dawn Shane, in 1965. They have two daughters, and 5 grandchildren.

References

  1. ^ https://www.bps.ac.uk/about/who-we-are/fellows-directory/professor-malcolm-rowland/f9fc56b2-d7f6-e311-88a7-001dd8b721a7
  2. ^ "Search for people | the University of Manchester".
  3. ^ "Distinguished Pharmaceutical Scientist: Malcolm Rowland (2006)". YouTube.
  4. ^ https://catalogue.libraries.london.ac.uk/search~S16?/aRowland%2C+M./arowland+m/-3%2C-1%2C0%2CB/frameset&FF=arowland+m&1%2C1%2C
  5. ^ "1967–1978: The Riegelman Chairship · History of the Department of Bioengineering and Therapeutic Sciences".
  6. ^ Benowitz, Neal; Forsyth, Ralph P.; Melmon, Kenneth L.; Rowland, Malcolm (July 1974). "Lidocaine disposition kinetics in monkey and man; I. Prediction by a perfusion model". Clinical Pharmacology & Therapeutics. 16 (1part1): 87–98. doi:10.1002/cpt1974161part187.
  7. ^ Rowland, Malcolm; Benet, Leslie Z.; Graham, Garry G. (April 1973). "Clearance concepts in pharmacokinetics". Journal of Pharmacokinetics and Biopharmaceutics. 1 (2): 123–136. doi:10.1007/BF01059626.
  8. ^ Pang, K. Sandy; Rowland, Malcolm (December 1977). "Hepatic clearance of drugs. I. Theoretical considerations of a 'well-stirred' model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance". Journal of Pharmacokinetics and Biopharmaceutics. 5 (6): 625–653. doi:10.1007/BF01059688.
  9. ^ Bonate, Peter L. (February 2020). "On the shoulders of giants…". Journal of Pharmacokinetics and Pharmacodynamics. 47 (1): 1. doi:10.1007/s10928-020-09674-4. PMID 31960232. S2CID 210717345.
  10. ^ Michael S. Roberts & Malcolm Rowland (1986). A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. Journal of Pharmacokinetics and Biopharmaceutics 14, 227–260. https://link.springer.com/article/10.1007%2FBF01106706
  11. ^ Cheung, S.Y.A., Rodgers, T., Aarons, L., Gueorguieva, I, Dickenson, G.L., Murby, S, Brown, C., Collins, B., Rowland, M (2018). Whole body physiologically based modelling of beta-blockers in the rat: Events in tissues and plasma following an intravenous bolus dose. Brit. J. Pharmacol. 175 67-83. PMID: 29053169, DOI: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.14071
  12. ^ Rodgers, T. and Rowland, M (2006). Physiologically-Based Pharmacokinetic Modeling 2: Predicting the Tissue Distribution of Acids, Very Weak Bases, Neutrals and Zwitterions. J. Pharm. Sci. 95 1238-57. PMID: 16639716 DOI: https://jpharmsci.org/article/S0022-3549(16)32034-2/fulltext
  13. ^ "Drug development | the University of Manchester".
  14. ^ https://www.capkr.manchester.ac.uk
  15. ^ Graham Lappin, Yoko Shishikura, Roeline Jochemsen, Richard John Weaver, Charlotte Gesson, Brian Houston, Berend Oosterhuisd, Ole J. Bjerrum, Grzegorz Grynkiewiczf, Jane Alder, Malcolm Rowland, Colin Garner (2011). Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur. J. Pharm. Sci 2011, 43 141–150; PMID: 21540108, DOI: https://www.sciencedirect.com/science/article/abs/pii/S0928098711001047?via%3Dihub
  16. ^ Tal Burt, Graeme Young, Wooin Lee, Hiroyuki Kusuhara, Oliver Langer, Malcolm Rowland, Yuichi Sugiyama (2020). Phase-0 including microdosing approaches: Time for mainstream application in drug development? Nature Reviews Drug Discovery Development. 19: 801-818. PMID: 32901140, DOI: https://www.nature.com/articles/s41573-020-0080-x
  17. ^ https://www.pkworkshops.com
  18. ^ https://https://www.eufeps.org/History.html
  19. ^ "Structure and statutes".
  20. ^ https://pharmacy.lwwhealthlibrary.com/book.aspx?bookid=2695
  21. ^ https://www.uu.se/en/about-uu/traditions/prizes/honorary-doctorates/pharmacy/
  22. ^ http://old.pharm.uoa.gr/an8ropino-dynamiko/epitimoi-didaktores.html
  23. ^ https://accp1.org/members/ACCP1/6Members/Past_Award_Winners.aspx
  24. ^ https://www.apotekarsocieteten.se/en/scholarships-and-prizes/scheele-award/former-laurates/
  25. ^ https://higherlogicdownload.s3.amazonaws.com/AAPS/6ab7f0bc-b417-4a16-bedb-21afc588c1d6/UploadedImages/Awards_page/historical_awards.pdf
  26. ^ https://www.ascpt.org/Portals/28/docs/Awards/Criteria%20and%20Past%20Recipients/2021%20Awards/Award%20Criteria%20and%20Past%20Recipients%202021%20Sheiner-Beal.pdf?ver=2021-05-03-114840-033
  27. ^ https://nvfarmacologie.nl/awards/ariens-award/
  28. ^ https://www.rpharms.com/about-us/news/details/Hanbury-and-Harrison-Medal-winners
  29. ^ https://www.fip.org/awards#Host-Madsen-Medal
Retrieved from "https://en.wikipedia.org/w/index.php?title=Malcolm_Rowland&oldid=1083364607"